{
  "symbol": "PFE",
  "year": 2024,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.1252,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.167
  },
  "top_positive": [
    {
      "sent": "EU JAPAN COVID-19 Vaccine (pediatric) (a) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months through 4 years of age Authorized September 2023 Approved August 2023 Approved September 2023 Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 5 through 11 years of age Authorized September 2023 Approved August 2023 Approved September 2023 Comirnaty (COVID-19 Vaccine) (b) Active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older Approved September 2023 Approved August 2023 Approved September 2023 Ngenla (somatrogon) (c) Pediatric growth hormone deficiency Approved June 2023 Approved February 2022 Approved January 2022 Prevnar 20/Apexxnar (Vaccine) Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae (adults) Approved June 2021 Approved February 2022 Filed September 2023 Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae (pediatric) Approved April 2023 Approved March 2024 Approved March 2024 TicoVac (Vaccine) Active immunization to prevent tick-borne encephalitis disease Approved August 2021 Approved March 2024 Paxlovid (d) (nirmatrelvir and ritonavir) COVID-19 in high-risk adults Approved May 2023 Approved February 2023 Approved July 2023 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura (adults) Approved February 2020 Approved April 2022 Prevention of episodic migraine (adults) Approved May 2021 Approved April 2022 Litfulo/Ritfulo (ritlecitinib) Alopecia areata Approved June 2023 Approved September 2023 Approved June 2023 Zavzpret (zavegepant) (intranasal) Acute treatment of migraine with or without aura (adults) Approved March 2023 Penbraya (PF-06886992) (Vaccine) Active immunization to prevent serogroups ABCWY meningococcal infections (adolescent and young adults) Approved October 2023 Filed June 2023 Abrysvo (Vaccine) Active immunization to prevent RSV infection (maternal) Approved August 2023 Approved August 2023 Approved January 2024 Active immunization to prevent RSV infection (older adults) Approved May 2023 Approved August 2023 Approved March 2024 Velsipity (etrasimod) Ulcerative colitis (moderately to severely active) Approved October 2023 Approved February 2024 Braftovi (encorafenib) and Mektovi (binimetinib) BRAF V600E -mutant metastatic non-small cell lung cancer (adults) Approved October 2023 Filed October 2023 (e) Elrexfio (elranatamab) Multiple myeloma triple-class relapsed/refractory Approved August 2023 Approved December 2023 Approved March 2024 44 PRODUCT INDICATION OR PROPOSED INDICATION APPROVED/FILED* U.S.",
      "score": 0.999
    },
    {
      "sent": "EU JAPAN COVID-19 Vaccine (pediatric) (a) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months through 4 years of age Authorized September 2023 Approved August 2023 Approved September 2023 Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 5 through 11 years of age Authorized September 2023 Approved August 2023 Approved September 2023 Comirnaty (COVID-19 Vaccine) (b) Active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older Approved September 2023 Approved August 2023 Approved September 2023 Ngenla (somatrogon) (c) Pediatric growth hormone deficiency Approved June 2023 Approved February 2022 Approved January 2022 Prevnar 20/Apexxnar (Vaccine) Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae (adults) Approved June 2021 Approved February 2022 Filed September 2023 Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae (pediatric) Approved April 2023 Approved March 2024 Approved March 2024 TicoVac (Vaccine) Active immunization to prevent tick-borne encephalitis disease Approved August 2021 Approved March 2024 Paxlovid (d) (nirmatrelvir and ritonavir) COVID-19 in high-risk adults Approved May 2023 Approved February 2023 Approved July 2023 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura (adults) Approved February 2020 Approved April 2022 Prevention of episodic migraine (adults) Approved May 2021 Approved April 2022 Litfulo/Ritfulo (ritlecitinib) Alopecia areata Approved June 2023 Approved September 2023 Approved June 2023 Zavzpret (zavegepant) (intranasal) Acute treatment of migraine with or without aura (adults) Approved March 2023 Penbraya (PF-06886992) (Vaccine) Active immunization to prevent serogroups ABCWY meningococcal infections (adolescent and young adults) Approved October 2023 Filed June 2023 Abrysvo (Vaccine) Active immunization to prevent RSV infection (maternal) Approved August 2023 Approved August 2023 Approved January 2024 Active immunization to prevent RSV infection (older adults) Approved May 2023 Approved August 2023 Approved March 2024 Velsipity (etrasimod) Ulcerative colitis (moderately to severely active) Approved October 2023 Approved February 2024 Braftovi (encorafenib) and Mektovi (binimetinib) BRAF V600E -mutant metastatic non-small cell lung cancer (adults) Approved October 2023 Filed October 2023 (e) Elrexfio (elranatamab) Multiple myeloma triple-class relapsed/refractory Approved August 2023 Approved December 2023 Approved March 2024 44 PRODUCT INDICATION OR PROPOSED INDICATION APPROVED/FILED* U.S.",
      "score": 0.999
    },
    {
      "sent": "EU JAPAN COVID-19 Vaccine (pediatric) (a) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months through 4 years of age Authorized September 2023 Approved August 2023 Approved September 2023 Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 5 through 11 years of age Authorized September 2023 Approved August 2023 Approved September 2023 Comirnaty (COVID-19 Vaccine) (b) Active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older Approved September 2023 Approved August 2023 Approved September 2023 Ngenla (somatrogon) (c) Pediatric growth hormone deficiency Approved June 2023 Approved February 2022 Approved January 2022 Prevnar 20/Apexxnar (Vaccine) Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae (adults) Approved June 2021 Approved February 2022 Filed September 2023 Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae (pediatric) Approved April 2023 Approved March 2024 Approved March 2024 TicoVac (Vaccine) Active immunization to prevent tick-borne encephalitis disease Approved August 2021 Approved March 2024 Paxlovid (d) (nirmatrelvir and ritonavir) COVID-19 in high-risk adults Approved May 2023 Approved February 2023 Approved July 2023 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura (adults) Approved February 2020 Approved April 2022 Prevention of episodic migraine (adults) Approved May 2021 Approved April 2022 Litfulo/Ritfulo (ritlecitinib) Alopecia areata Approved June 2023 Approved September 2023 Approved June 2023 Zavzpret (zavegepant) (intranasal) Acute treatment of migraine with or without aura (adults) Approved March 2023 Penbraya (PF-06886992) (Vaccine) Active immunization to prevent serogroups ABCWY meningococcal infections (adolescent and young adults) Approved October 2023 Filed June 2023 Abrysvo (Vaccine) Active immunization to prevent RSV infection (maternal) Approved August 2023 Approved August 2023 Approved January 2024 Active immunization to prevent RSV infection (older adults) Approved May 2023 Approved August 2023 Approved March 2024 Velsipity (etrasimod) Ulcerative colitis (moderately to severely active) Approved October 2023 Approved February 2024 Braftovi (encorafenib) and Mektovi (binimetinib) BRAF V600E -mutant metastatic non-small cell lung cancer (adults) Approved October 2023 Filed October 2023 (e) Elrexfio (elranatamab) Multiple myeloma triple-class relapsed/refractory Approved August 2023 Approved December 2023 Approved March 2024 44 PRODUCT INDICATION OR PROPOSED INDICATION APPROVED/FILED* U.S.",
      "score": 0.999
    }
  ],
  "top_negative": [
    {
      "sent": "AND SUBSIDIARY COMPANIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (MILLIONS) Three Months Ended PRODUCT PRIMARY INDICATION OR CLASS March 31, 2024 April 2, 2023 BeneFIX Hemophilia B 103 109 Oxbryta Sickle cell disease 84 71 Cibinqo Atopic dermatitis 42 16 All other Hospital (c) Various 1,149 1,197 All other Specialty Care Various 205 188 Oncology $ 3,549 $ 2,997 Ibrance HR-positive/HER2-negative metastatic breast cancer 1,054 1,144 Xtandi (d) mCRPC, nmCRPC, mCSPC, nmCSPC 418 339 Padcev Locally advanced or metastatic urothelial cancer 341 \u2014 Oncology biosimilars (e) Various 264 412 Adcetris Hodgkin lymphoma and certain T-cell lymphomas 257 \u2014 Inlyta Advanced RCC 237 259 Lorbrena ALK-positive metastatic NSCLC 164 112 Bosulif Philadelphia\u00a0chromosome\u2013positive\u00a0chronic myelogenous leukemia 145 150 Braftovi/Mektovi Metastatic melanoma in patients with a BRAF V600E/K mutation and for metastatic NSCLC in patients with a BRAF V600E mutation; and, for Braftovi, in combination with Erbitux (cetuximab) (f) for the treatment of BRAF V600E -mutant mCRC after prior therapy 116 103 Tukysa Unresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer 106 \u2014 Tivdak Recurrent or metastatic cervical cancer 28 \u2014 Talzenna In combination with Xtandi (enzalutamide) for adult patients with HRR gene-mutated mCRPC; treatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer 23 10 All other Oncology Various 397 467 BUSINESS INNOVATION $ 275 $ 313 Pfizer CentreOne (g) Various 258 308 Pfizer Ignite Various 17 4 BIOPHARMA $ 14,604 $ 18,173 PFIZER U.S.",
      "score": -0.9569
    },
    {
      "sent": "NDA New Drug Application Nimbus Nimbus Therapeutics, LLC nmCRPC non-metastatic castration-resistant prostate cancer 3 nmCSPC non-metastatic castration-sensitive prostate cancer NSCLC non-small cell lung cancer ODT oral disintegrating tablet ORD Oncology Research and Development OTC over-the-counter Paxlovid* an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets) PC1 Pfizer CentreOne Pharmacia Pharmacia LLC (formerly Pharmacia Corporation) PP&E Property, plant and equipment PRD Pfizer Research and Development Prevnar family Includes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult) PsA psoriatic arthritis RA rheumatoid arthritis RCC renal cell carcinoma R&D research and development RSV respiratory syncytial virus S&P Standard & Poor\u2019s Seagen Seagen Inc.",
      "score": -0.9349
    },
    {
      "sent": "NDA New Drug Application Nimbus Nimbus Therapeutics, LLC nmCRPC non-metastatic castration-resistant prostate cancer 3 nmCSPC non-metastatic castration-sensitive prostate cancer NSCLC non-small cell lung cancer ODT oral disintegrating tablet ORD Oncology Research and Development OTC over-the-counter Paxlovid* an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets) PC1 Pfizer CentreOne Pharmacia Pharmacia LLC (formerly Pharmacia Corporation) PP&E Property, plant and equipment PRD Pfizer Research and Development Prevnar family Includes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult) PsA psoriatic arthritis RA rheumatoid arthritis RCC renal cell carcinoma R&D research and development RSV respiratory syncytial virus S&P Standard & Poor\u2019s Seagen Seagen Inc.",
      "score": -0.9349
    }
  ],
  "forward_snippets": [
    "The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.",
    "We will finalize the amounts recognized as soon as possible but no later than one year from the acquisition date.",
    "The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.",
    "We will finalize the amounts recognized as soon as possible but no later than one year from the acquisition date.",
    "common shareholders 0.81 The unaudited supplemental pro forma consolidated results do not purport to reflect what the combined company\u2019s results of operations would have been had the acquisition occurred on January 1, 2022, nor do they project the future results of operations o\nguidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements."
  ]
}